(Q36415312)

14 August 2017

1 reference

title

Cancer-related anemia and recombinant human erythropoietin--an updated overview (English)

1 reference

14 August 2017

1 reference

cancer-related anemia

1 reference

Julia Bohlius

1

0 references

Sven Trelle

object named as

Sven Trelle

series ordinal

3

0 references

Olaf Weingart

series ordinal

2

object named as

Olaf Weingart

1 reference

14 August 2017

4

Andreas Engert

1 reference

14 August 2017

language of work or name

1 reference

1 March 2006

1 reference

Nature Clinical Practice Oncology

14 August 2017

published in

1 reference

14 August 2017

volume

3

1 reference

14 August 2017

issue

3

1 reference

14 August 2017

page(s)

152-164

1 reference

Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Prevalence and outcomes of anemia in cancer: a systematic review of the literature

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Chemotherapy-induced anemia in adults: incidence and treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

The anaemia of cancer: death by a thousand cuts

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Decreased erythropoietin response in patients with the anemia of cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Cisplatin-associated anemia: an erythropoietin deficiency syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Symptomatology of anemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

The impact of hemoglobin levels on fatigue and quality of life in cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

The level of haemoglobin in anaemic cancer patients correlates positively with quality of life

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Assessment and management of cancer-related fatigue in adults

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Evidence-based treatment for cancer-related fatigue

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Hypoxia and anemia: effects on tumor biology and treatment resistance

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Role of red blood cells in pharmacokinetics of chemotherapeutic agents

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: A possible oxygen effect

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Risks of blood transfusion

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Transfusion medicine. First of two parts--blood transfusion

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Red blood cell transfusion strategies

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Serendipity and the use of random donor platelets in fetomaternal alloimmune thrombocytopenia (FMAIT)

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Expression cloning of the murine erythropoietin receptor

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Clinical and economic comparison of epoetin alfa and darbepoetin alfa

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Erythropoietin, uncertainty principle and cancer related anaemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Impact of epoetin beta on quality of life in patients with malignant disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Methodologic issues in assessing the quality of life of cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Breast cancer trial with erythropoietin terminated unexpectedly

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Functional significance of erythropoietin receptor expression in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Beneficial and ominous aspects of the pleiotropic action of erythropoietin

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Platelet-erythrocyte interactions enhance alpha(IIb)beta(3) integrin receptor activation and P-selectin expression during platelet recruitment: down-regulation by aspirin ex vivo

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Erythropoietin for anaemia in cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: A randomized, controlled study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0451

7 January 2021

Identifiers

DOI

10.1038/NCPONC0451

1 reference

Dimensions Publication ID

14 August 2017

1050226120

0 references

Fatcat ID

release_zq3tpk72o5ahhg6tmhzgk63uxy

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zq3tpk72o5ahhg6tmhzgk63uxy

24 November 2022

mapped directly with Wikidata item

1 reference